MajorDirect oral anticoagulants (factor Xa inhibitors)×Systemic antimycotics. Imidazole derivatives
Updated · Methodology
Mechanism
Ketoconazole strongly inhibits the transporter P-glycoprotein (P-gp) and the enzyme CYP3A4 (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Edoxaban is a P-gp substrate (edoxaban SmPC, EMA). Ketoconazole 400 mg once daily for 7 days increased the edoxaban area under the concentration–time curve (AUC) by 87% and its peak concentration by 89% (edoxaban SmPC, EMA). According to the ketoconazole SmPC, both values rose 1.8-fold (ketoconazole SmPC, EMA). In the EU, ketoconazole tablets are indicated for endogenous Cushing's syndrome in adults and adolescents over 12 years (ketoconazole SmPC, EMA). After ketoconazole cream was applied to the skin of adults, no measurable ketoconazole levels were found in plasma (ketoconazole cream SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).
Management
With oral ketoconazole, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The ketoconazole SmPC also says to reduce the edoxaban dose during combined use according to the edoxaban SmPC (ketoconazole SmPC, EMA). The European Heart Rhythm Association table gives the same 30 mg dose (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). Ketoconazole can damage the liver. Do not start it if liver enzymes are more than twice the upper limit of normal. Check liver enzymes and bilirubin before treatment, weekly for the first month and then monthly for 6 months (ketoconazole SmPC, EMA). Edoxaban is contraindicated in liver disease with coagulopathy and a clinically relevant bleeding risk (edoxaban SmPC, EMA). Promptly evaluate any signs of blood loss (edoxaban label, US Food and Drug Administration, FDA). Haemoglobin and haematocrit may help detect hidden bleeding. Stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors. In deep vein thrombosis and pulmonary embolism, the dose is reduced to 30 mg with certain P-gp inhibitors. In the trial, these included a short course of oral ketoconazole (edoxaban label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2